DRAFT Innovative Solutions Opening (ISO) ARPA-H Rare disease AI/ML for Precision Integrated Diagnostics (RAPID)
ID: ARPA-H-SOL-25-119Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNIH ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)Bethesda, MD, 208920004, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT (AN13)
Timeline
  1. 1
    Posted Jan 10, 2025, 12:00 AM UTC
  2. 2
    Updated Jan 10, 2025, 12:00 AM UTC
  3. 3
    Due Apr 11, 2025, 9:00 PM UTC
Description

The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Final Innovative Solutions Opening (ISO) under the Rare Disease AI/ML for Precision Integrated Diagnostics (RAPID) program. This initiative aims to significantly enhance the speed and accuracy of diagnosing rare diseases, which affect approximately 30 million Americans, by developing innovative diagnostic support tools and a sustainable data platform optimized for AI-driven solutions. The RAPID program encompasses two phases over 4.5 years, focusing on extensive data curation, multimodal patient data collections, and the establishment of an AI-driven data commons, with the goal of reducing diagnostic delays and improving health management for underserved populations. Proposals are due by April 24, 2025, and interested parties can direct inquiries to the RAPID Email Box at RAPID@ARPA-H.gov.

Point(s) of Contact
RAPID Email Box
RAPID@ARPA-H.gov
Files
Title
Posted
Jan 10, 2025, 5:04 PM UTC
The Advanced Research Projects Agency for Health (ARPA-H) has issued a solicitation for the "Rare Disease AI/ML for Precision Integrated Diagnostics" program, known as RAPID. This initiative seeks proposals aimed at expediting the diagnosis of rare diseases through the aggregation and analysis of extensive health data sets using artificial intelligence (AI) and machine learning (ML). The program focuses on developing tools for large-scale identification of undiagnosed patients, reducing diagnostic delays by at least 50%, and enhancing accessibility for underserved populations. The RAPID program will unfold over 4.5 years, divided into two phases: Phase I focuses on foundational data gathering and system development, while Phase II will emphasize deployment and validation of diagnostic models. The program includes three technical areas (TAs): TA1 involves creating a large-scale rare disease dataset; TA2 emphasizes user-friendly, patient-reporting tools for data collection; and TA3 establishes a Rare Disease Data Commons to facilitate model development. Eligible entities may submit multiple proposals, with attention to patient experience and engagement. Proposals will undergo independent verification and validation to ensure data quality and adherence to defined metrics. The RAPID program represents a significant federal investment in addressing the challenges posed by rare diseases, aiming for substantial improvements in patient outcomes and healthcare accessibility.
Feb 21, 2025, 5:05 PM UTC
The Innovative Solutions Opening (ISO) titled "Rare Disease AI/ML for Precision Integrated Diagnostics" (RAPID) by the Advanced Research Projects Agency for Health (ARPA-H) aims to improve rare disease diagnostics through advanced data aggregation and analytic techniques. The program seeks proposals to optimize large-scale health data collection and enhance diagnostic support tools, focusing particularly on underdiagnosed populations. Over a proposed 4.5-year span, RAPID will operate in two phases, targeting areas such as creating comprehensive rare disease datasets, developing novel diagnostic indicators, and fostering collaborations for real-world validation of diagnostic models. Key technical areas include: 1. Aggregating existing rare disease health data (TA1) 2. Collecting novel data directly from patients to uncover diagnostic indicators (TA2) 3. Creating a Rare Disease Data Commons for analytical evaluation (TA3) The initiative also emphasizes equitable access to diagnostics, aiming to reduce the time to diagnosis significantly and improve patient outcomes. Eligible applicants are encouraged to collaborate within a network that actively includes patient experiences. Timeline milestones and rigorous evaluation criteria ensure accountability and facilitate continuous improvement throughout the program's execution. This solicitation offers a vital funding opportunity to innovators in the field, aiming to catalyze advancements in rare disease diagnostics for better healthcare outcomes.
Mar 20, 2025, 6:06 PM UTC
The Innovative Solutions Opening (ISO) by the Advanced Research Projects Agency for Health (ARPA-H) targets rare disease diagnosis via the Rare Disease AI/ML for Precision Integrated Diagnostics (RAPID) program. The goal is to radically improve the speed and accuracy of diagnosing rare conditions, which affect approximately 30 million Americans and often result in an extensive diagnostic journey lasting years. This solicitation invites proposals for innovative solutions to aggregate existing data, collect novel patient information, and create a sustainable data platform optimized for AI diagnostic development. RAPID comprises two phases over 4.5 years, focusing on extensive data curation, accessibility enhancements, and equitable patient engagement. Key technical areas include establishing a large-scale rare disease dataset (TA1), creating multimodal patient data collections (TA2), and developing an AI-driven data commons for analysis and diagnostics (TA3). The program emphasizes patient experience, inclusivity, and the integration of diverse health data sources. Expected outcomes include a significant reduction in diagnostic delays and improved health management for underserved populations. With no established budget ceilings, project awards will be based on the viability of proposals and overall program impact, fostering rapid advancements in rare disease diagnostics and treatment accessibility.
Mar 20, 2025, 6:06 PM UTC
The document outlines cost proposal requirements for government solicitation submissions. It emphasizes that unpriced options will not be accepted, and proposers must provide detailed, accurate cost breakdowns to assist government personnel in evaluating their proposals. Key sections include total direct labor costs, general and administrative costs, and other direct costs, each requiring meticulous calculations and justifications. Proposers are to present their fiscal year accounting periods and ensure all cost components align with the totals in the provided spreadsheet. The document specifies the necessity of separating labor and indirect costs while maintaining compliance with government regulations regarding profit margins, particularly in equipment-related expenses. Moreover, it stresses that proposed labor categories must reflect proper classifications and rates to facilitate evaluation and negotiation, reinforcing the importance of well-prepared submissions for successful contract awards. This summary highlights the essential procedural and financial elements for effectively navigating government RFPs and grants.
Mar 20, 2025, 6:06 PM UTC
The document outlines a framework for identifying and analyzing rare diseases as part of federal and state grant initiatives. It emphasizes a systematic approach to capture essential data: disease names, synonyms, classification codes (OrphaCode, OMIM, ICD-11), estimated prevalence, sample size requirements, and recognized diagnostic challenges. Each entry should include detailed epidemiology, potential demographic biases, available data sources, and the projected timeline for gathering enough data. The document mandates evaluations of disease prioritization categories, justifying the focus on particular diseases based on their impact and existing data gaps. The overall goal is to develop comprehensive datasets for more effective public health strategies and targeted medical research, which is significant in informing funding decisions within government RFPs and grants aimed at rare diseases. This structured approach underlines the importance of collaborative efforts in addressing health disparities and improving healthcare outcomes.
Mar 20, 2025, 6:06 PM UTC
The document outlines a Statement of Work (SOW) template designed for government proposals, specifically addressing tasks relevant to federal and state grants and RFPs. It emphasizes a structured breakdown of tasks and subtasks, requiring detailed descriptions that include goals, key actions, primary organizations, completion criteria, measurable milestones, and deliverables. The SOW is intended to provide clarity and accountability in project execution. Each task and subtask must outline specific activities, identify potential obstacles, and establish quantifiable metrics to assess performance. The comprehensive nature of the template aims to ensure that all essential components of project management are considered, fostering effective collaboration among contractors and stakeholders. This structured approach is crucial for successful project delivery and compliance with governmental requirements in grant and RFP contexts.
Similar Opportunities
Office-Wide Innovative Solutions Opening for Health Science Futures (HSF)
Buyer not available
The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Innovative Solutions Opening (ISO) aimed at advancing healthcare technologies. This initiative seeks innovative, disease-agnostic research projects that can significantly improve health outcomes, focusing on areas such as maternal and fetal health, genetic therapies, and novel diagnostic tools. The solicitation emphasizes the development of transformative solutions rather than incremental research, with submissions required to follow a two-step process: an initial solution summary followed by a full proposal based on feedback received. Interested parties must submit their solution summaries by March 3, 2029, via the designated ARPA-H portal, and are encouraged to review the detailed submission guidelines outlined in the provided documentation.
ARPA-H ImagiNg Data EXchange (INDEX)
Buyer not available
The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Imaging Data Exchange (INDEX) program aimed at enhancing access to medical imaging data. The initiative seeks to develop a sustainable platform that connects data providers, users, and service providers, leveraging artificial intelligence and machine learning to address the growing demand for medical imaging amidst a shortage of qualified radiologists. This program is structured in two phases: Phase 0 focuses on business model development, while Phase 1 involves system design and participant enrollment, with an emphasis on ensuring diverse and representative datasets. Interested parties must submit their Solution Summary by January 28, 2025, and Full Proposals by April 18, 2025, with inquiries directed to the INDEX Team at INDEX@arpa-h.gov.
Office-Wide Innovative Solutions Opening for Proactive Health Office (PHO)
Buyer not available
The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting innovative research proposals aimed at enhancing health outcomes via the Proactive Health Office (PHO). The initiative focuses on developing solutions that prioritize disease prevention, early intervention, and scalable wellness-promoting behaviors, moving away from traditional reactive healthcare models. This opportunity is significant for entities capable of delivering transformative health solutions, with proposals evaluated based on scientific merit and relevance, and funding potentially awarded through Other Transactions or Cooperative Agreements. Interested parties must submit a mandatory solution summary by March 3, 2029, and can direct inquiries to the designated contact via the provided submission platforms.
Office-Wide Innovative Solutions Opening for Scalable Solutions Office (SSO)
Buyer not available
The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting innovative solutions aimed at enhancing healthcare accessibility, affordability, and scalability. This opportunity invites universities, non-profits, small businesses, and similar entities to submit solution summaries and proposals that address health disparities, improve the distribution of healthcare technologies, and advance biomanufacturing innovations. The solicitation emphasizes the development of scalable technologies and collaborative distribution networks, with a focus on interdisciplinary approaches to revolutionize biomedicine and public health outcomes. Interested parties must submit their solution summaries by March 3, 2029, and can find further details and submission guidelines at https://solutions.arpa-h.gov. For inquiries, questions should be directed to the same website.
Office-Wide Innovative Solutions Opening for Resilient Systems Office (RSO)
Buyer not available
The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting innovative solutions aimed at enhancing the resilience of healthcare systems via its Resilient Systems Office (RSO). This opportunity invites submissions from eligible entities, including universities, nonprofits, and small businesses, to address systemic challenges in healthcare and public health by leveraging cutting-edge technologies that improve care quality and availability. The solicitation emphasizes the importance of sociotechnical system innovations and adaptive solutions that enhance the reliability and interoperability of health ecosystems. Interested parties must submit solution summaries for feedback before full proposal submissions, with the solicitation open until March 3, 2029. For further inquiries, submissions should be directed to the designated online platforms, and the primary contact email is provided in the solicitation details.
ADAPT Contract Research Organization Support Services
Buyer not available
The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is seeking proposals for the ADAPT Contract Research Organization (CRO) Support Services aimed at enhancing precision cancer therapy. The primary objective is to develop an adaptive cancer treatment platform that integrates advanced analysis techniques and biomarker discovery to improve treatment strategies for metastatic cancer, focusing on therapy recommendations, evolutionary clinical trials, and a treatment analysis platform. This initiative is crucial for advancing cancer research and improving patient outcomes by matching therapies with evolving tumor biology in real-time. Proposals are due by April 11, 2025, with questions accepted until April 3, 2025. Interested parties can contact Steven Snyder at steven.snyder@arpa-h.gov or Clare Sanchez at clare.sanchez@arpa-h.gov for further information.
Ocular Laboratory for Analysis of Biomarkers (OCULAB)
Buyer not available
The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Ocular Laboratory for Analysis of Biomarkers (OCULAB) program, aimed at advancing the diagnosis and treatment of ocular conditions, particularly dry eye disease (DED). The initiative seeks innovative solutions to develop a continuous monitoring biosensor integrated with therapeutic delivery systems, leveraging AI for non-invasive treatment methods. This program is significant for enhancing patient care and healthcare equity through advanced biomarker analysis and technology. Interested parties can contact the OCULAB Team at OCULAB@ARPA-H.gov for further information, with multiple awards anticipated as part of this funding opportunity, which is open until March 31, 2025.
iNDI ALFAtag cell lines for the iPSC Neurodegenetive Disease Initiative (iNDI) project
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of iNDI ALFAtag cell lines as part of the iPSC Neurodegenerative Disease Initiative (iNDI) project. The objective is to generate up to 230 isogenic iPSC cell lines, including fluorescent ALFAtags for visualization, adhering to established quality control standards for research on Alzheimer's disease and related dementias. This initiative is crucial for advancing scientific understanding of neurodegenerative diseases and creating a publicly accessible cell repository. Interested vendors must submit their proposals by April 15, 2025, at 12:00 PM Eastern Time, to Andrea Clay at amcgee@nih.gov, referencing solicitation number 75N95025Q00078.
A Human Multi-Organ Tissue Equivalent Platform to Model High Consequence Threat Agents
Buyer not available
The Department of Defense, through the Army Medical Research Acquisition Activity, is seeking a contractor to develop a Human Multi-Organ Tissue Equivalent Platform aimed at modeling high consequence threat agents. This initiative focuses on creating a micro-engineered organ/tissue equivalent platform that will facilitate the modeling of pathogenic outcomes from emerging infectious diseases and the testing of medical countermeasures, particularly for respiratory viruses such as SARS-CoV-2, MERS, and pandemic H1N1 influenza. The project is critical for enhancing the military's capability to protect warfighters from both natural and manmade threats, ensuring rapid identification of effective medical responses. Interested contractors must submit their capabilities by 10:00 AM EST on April 14, 2025, and can direct inquiries to Kirstin L. Quinn at Kirstin.L.Quinn.civ@health.mil.
Remote Health Readiness Program 4 (RHRP-4)
Buyer not available
The Department of Defense, through the Defense Health Agency (DHA), is soliciting proposals for the Remote Health Readiness Program 4 (RHRP-4), aimed at providing comprehensive medical and dental readiness services to military personnel, including both active and reserve components enrolled in TRICARE Prime Remote. The contract, valued at a maximum of $1.61 billion, will span ten years and includes a transition-in period followed by a base period and nine optional years of performance, emphasizing the importance of maintaining a medically ready force. Key services required under this contract include health assessments, treatment modalities, and logistical support for scheduling and implementing services, ensuring compliance with military health standards. Interested contractors should direct inquiries to Nakaura C. Yusuf at nakaura.c.yusuf.civ@health.mil, with proposals due by April 26, 2025.